A detailed history of Geode Capital Management, LLC transactions in Aerovate Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 291,887 shares of AVTE stock, worth $758,906. This represents 0.0% of its overall portfolio holdings.

Number of Shares
291,887
Previous 317,174 7.97%
Holding current value
$758,906
Previous $526,000 15.97%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$1.61 - $2.09 $40,712 - $52,849
-25,287 Reduced 7.97%
291,887 $610,000
Q2 2024

Aug 09, 2024

BUY
$1.41 - $30.75 $49,933 - $1.09 Million
35,414 Added 12.57%
317,174 $526,000
Q1 2024

May 13, 2024

BUY
$17.68 - $29.57 $86,013 - $143,858
4,865 Added 1.76%
281,760 $8.33 Million
Q4 2023

Feb 13, 2024

BUY
$9.58 - $24.25 $259,493 - $656,859
27,087 Added 10.84%
276,895 $6.27 Million
Q3 2023

Nov 13, 2023

BUY
$12.9 - $18.88 $603,075 - $882,640
46,750 Added 23.02%
249,808 $3.39 Million
Q2 2023

Aug 11, 2023

BUY
$15.63 - $22.01 $243,187 - $342,453
15,559 Added 8.3%
203,058 $3.48 Million
Q1 2023

May 15, 2023

BUY
$19.17 - $27.7 $170,670 - $246,613
8,903 Added 4.98%
187,499 $3.78 Million
Q4 2022

Feb 13, 2023

BUY
$15.92 - $30.52 $143,232 - $274,588
8,997 Added 5.3%
178,596 $5.23 Million
Q3 2022

Nov 14, 2022

BUY
$14.77 - $25.79 $50,764 - $88,640
3,437 Added 2.07%
169,599 $2.81 Million
Q2 2022

Aug 12, 2022

SELL
$10.8 - $16.91 $313,470 - $490,812
-29,025 Reduced 14.87%
166,162 $2.6 Million
Q1 2022

May 13, 2022

BUY
$8.25 - $18.33 $309,020 - $686,586
37,457 Added 23.75%
195,187 $3.58 Million
Q4 2021

Feb 11, 2022

BUY
$9.14 - $21.54 $395,825 - $932,832
43,307 Added 37.85%
157,730 $1.86 Million
Q3 2021

Nov 12, 2021

BUY
$11.76 - $22.49 $1.35 Million - $2.57 Million
114,423 New
114,423 $2.4 Million

Others Institutions Holding AVTE

About Aerovate Therapeutics, Inc.


  • Ticker AVTE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,448,100
  • Market Cap $63.6M
  • Description
  • Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...
More about AVTE
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.